None listed
Conditions
Brief summary
Leishmaniasis is a parasitic disease that is endemic in developing countries. The incidence of leishmaniasis is more than 400,000 cases annually and the prevalence of all form of leishmaniasis is more than twelve millions. Although cutaneous leishmaniasis (CL) is a self- healing disease , the duration of the disease is long and requeries several months and somtimes years before complete recovery , depending on the species of the infecting parasite . After recovery, a disfiguring scar can be left , which may destroy underlying structures like the nose or ear or cause psychological suffering of patients . The first line drug for treatment of CL., according to WHO recommendation , is the pentavalent comounds such as meglomine antimoniate (Glucantime). Other treatment for cutaneous leishmaniasis are intralesinal injection of meglomine antimonate, terbinafine , paramonycin ointment , and physical treatment including cryotherapy .the aim of this atudy is to determine the efficacy of topical terbinafine in the treatment of cutaneous leishmaniasis.
Interventions
Topical terbinafine 2% cream twice daily until 10 weeks was applied on the cutaneous leishmaniasis lesions
+ intralesional injection of glucantime (435 mg of sb5+, active antimony) once per week until 10 weeks
Sponsors
Kerman medical university
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
2 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
age>2 years, the size of lesion<3cm, the number of lesions<4, the patients whom did not injected glucantim, the patinets whom did not receive any treatment for leishmaniasis within last month.
Exclusion criteria
pregnancy, lactation, the lesions of articular area.
Outcome results
None listed